invests 170 million euros in French vaccines facility
Send a link to a friend
[October 12, 2017] PARIS
(Reuters) - Sanofi will invest 170 million euros ($202 million) to
expand its vaccines manufacturing site at Val-de-Reuil in north-western
France, in a drive aimed at boosting the production of one of its
The French drugmaker said on Thursday that the new facility would
allow its Sanofi Pasteur vaccines division to expand the supply of
the VaxigripTetra product to up to 70 countries. Production at the
new facility will start from 2022 onwards.
"Influenza continues be a major public health problem around the
world, causing serious complications, hospitalizations and deaths,
mostly for certain high-risk individuals," said David Loew,
executive vice president at Sanofi and head of Sanofi Pasteur.
"As a global leader in flu vaccines, this expansion reinforces
Sanofi Pasteur's ability to tackle this underestimated health
challenge," he added.
Annual influenza epidemics result in three to five million cases of
severe illness worldwide and 250,000-500,000 deaths, according to
the World Health Organisation (WHO).
VaxigripTetra, which is currently available in 20 European
countries, works as a "quadrivalent" vaccine that protects against
four strains of the virus also known as flu.
[to top of second column]
Leading manufacturers of seasonal flu vaccines include Sanofi,
GlaxoSmithKline and CSL's Seqirus, which includes the old Novartis
flu vaccine business.
(Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta)
[© 2017 Thomson Reuters. All rights
Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.